Author

N. Carels

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

N. Fintelman-Rodrigues· 2 shared A. Ferreira· 1 shared A. R. Matos· 1 shared C. d. Q. Sacramento· 1 shared C. E. Pedreira· 1 shared C. Q. Sacramento· 1 shared C. R. Alves· 1 shared C. Ribeiro Lima· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

N. Fintelman-Rodrigues

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

OPTIMIZING THERAPEUTIC TARGETS FOR BREAST CANCER USING BOOLEAN NETWORK MODELS

D. Sgariglia, F. R. Goncalves Carneiro, L. A. Vidal de Carvalho, C. E. Pedreira, N. Carels, F. A. Barbosa da Silva

This study uses Boolean network models to identify therapeutic targets in breast cancer by simulating transitions between cancer and apoptosis attractors using RNA-seq data.

bioRxiv · May 10, 2023Cancer Biology

SARS-CoV-2 proteins bind heme and hemoglobin

S. G. De-Simone, G. C. Lechuga, F. Souza-Silva, C. d. Q. Sacramento, M. R. d. O. Trugilho, R. H. Valente, P. Napoleao-Pego, S. d. S. G. Dias, N. Fintelman-Rodrigues, J. R. Temerozzo, N. Carels, C. R. Alves, M. C. d. S. Pereira, D. W. Provance-Jr, T. M. De-Simone

This paper shows SARS-CoV-2 proteins bind hemin and hemoglobin, with hemin inhibiting viral replication and interacting with the Spike protein's RBD region.

bioRxiv · Apr 16, 2021 · PreprintBiochemistry

Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production

N. Fintelman-Rodrigues, C. Q. Sacramento, C. Ribeiro Lima, F. Souza da Silva, A. Ferreira, M. Mattos, C. S. de Freitas, V. Cardoso Soares, S. da Silva Gomes Dias, J. R. Temerozo, M. Miranda, A. R. Matos, F. A. Bozza, N. Carels, C. Roberto Alves, , T. M. L. Souza

This study shows that atazanavir inhibits SARS-CoV-2 replication and reduces pro-inflammatory cytokine production in vitro.

Antimicrobial Agents and Chemotherapy · Sep 21, 2020Peer-reviewedMicrobiology